Dataset from A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00007341
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety of study drug PLX3397 at 3 dose levels
(800 mg/day, 1000 mg/day, and 1200 mg/day) and explore the efficacy in patients with relapsed
or refractory acute myeloid leukemia (AML). Additional dose levels beyond 1200 mg/day may be
considered based on safety and efficacy observations.
创建时间：
2024-11-26
